Drug General Information
Drug ID	D03JTG
Former ID	DIB010509
Drug Name	Fruquintinib
Synonyms	HMPL-013
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 3	[525024]
Company	Hutchison Medipharma Enterprises Ltd
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Vascular endothelial growth factor receptor 1	Target Info	Inhibitor	[533061]
	Vascular endothelial growth factor receptor 2	Target Info	Inhibitor	[533061]
	Vascular endothelial growth factor receptor 3	Target Info	Inhibitor	[533061]
KEGG Pathway	Ras signaling pathway
	Rap1 signaling pathway
	Cytokine-cytokine receptor interaction
	HIF-1 signaling pathway
	Endocytosis
	PI3K-Akt signaling pathway
	Focal adhesion
	Transcriptional misregulation in cancer
	Rheumatoid arthritishsa04014:Ras signaling pathway
	VEGF signaling pathway
	Proteoglycans in cancerhsa04014:Ras signaling pathway
NetPath Pathway	IL2 Signaling PathwayNetPath_9:TNFalpha Signaling Pathway
PANTHER Pathway	Angiogenesis
	VEGF signaling pathway
Pathway Interaction Database	Glypican 1 network
	HIF-2-alpha transcription factor network
	S1P3 pathway
	VEGF and VEGFR signaling network
	VEGFR1 specific signals
	Signaling events mediated by VEGFR1 and VEGFR2hif2pathway:HIF-2-alpha transcription factor network
	Beta3 integrin cell surface interactions
	Signaling events mediated by TCPTP
	SHP2 signaling
	S1P1 pathway
	Integrins in angiogenesis
	Signaling events mediated by VEGFR1 and VEGFR2
	Notch-mediated HES/HEY networkvegf_vegfr_pathway:VEGF and VEGFR signaling network
	VEGFR3 signaling in lymphatic endothelium
Reactome	Neurophilin interactions with VEGF and VEGFR
	VEGF binds to VEGFR leading to receptor dimerizationR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
	VEGF binds to VEGFR leading to receptor dimerization
	Integrin cell surface interactions
	EPHA-mediated growth cone collapse
	VEGFA-VEGFR2 Pathway
	VEGFR2 mediated cell proliferationR-HSA-195399:VEGF binds to VEGFR leading to receptor dimerization
WikiPathways	Focal Adhesion
	Signaling by VEGF
	AngiogenesisWP306:Focal Adhesion
	Nifedipine Activity
	Cardiac Progenitor Differentiation
	AngiogenesisWP1919:Signaling by VEGF
References
Ref 525024	ClinicalTrials.gov (NCT02314819) A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients ???RESCO). U.S. National Institutes of Health.
Ref 533061	Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.